According to a report today on Xconomy.com, the U.S. Food & Drug Administration has approved the Progensa® PCA3 test developed by Gen-Probe.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, PCA3, risk, test | 4 Comments »
FDA approves Gen-Probe PCA3 test (Progensa)
Posted on February 15, 2012 by Sitemaster
Has Sebelius overruled USPSTF recommendation on PSA screening?
Posted on January 21, 2012 by Sitemaster
According to an announcement on the web site of Congressmen Dennis Kucinich late yesterday, HHS Secretary Kathleen Sebelius has agreed to overule the draft recommendation issued by the U.S. Preventive Services Task Force (USPSTF) related to the use of PSA testing as a means to detect prostate cancer.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, PSA, rfisk, screening, testing | 9 Comments »
Genomic Health initiates validation study of multi-gene test for prostate cancer
Posted on January 10, 2012 by Sitemaster
According to a media release issued by Genomic Health on Monday this week, the company has initiated a large clinical validation study of its Oncotype DX® test for prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, OncType DX, risk | 2 Comments »
The end of EPCA-1 and EPCA-2 as a diagnostic/prognostic test for prostate cancer
Posted on January 4, 2012 by Sitemaster
According to a news report this morning, a paper originally published in Urology (the Gold Journal) in 2007, and that reported that “early prostate cancer antigen” (EPCA) had the potential to replace the PSA test, has been retracted by the authors.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, EPCA-1, EPCA-2, risk | Leave a Comment »
Just more déjâ vu all over again
Posted on January 3, 2012 by Sitemaster
The new NCCN patient guidelines — a great improvement over last time
Posted on December 26, 2011 by Sitemaster
We have now had the chance to look carefully through the new, patient-specific guidelines on prostate cancer issued by the National Comprehensive Cancer Network (NCCN) just before the Holidays. They are not perfect, but they are certainly a vast improvement over the NCCN’s first attempt.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, guideline, Management, NCCN, patient, risk | 16 Comments »
Prostate cancer risk: an investigative journalist’s tale
Posted on December 20, 2011 by Sitemaster
When Paul VanDervelder was told his PSA had spiked, he did what many men do. He panicked! But then he did what he was trained to do as an investigative journalist. He investigated.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, PSA, risk | 7 Comments »
Prostate cancer screening (in Germany): curative or harmful?
Posted on November 14, 2011 by Sitemaster
The debate over the merits and risks of widespread screening for prostate cancer using the PSA test is hardly confined to the USA. A new article (in German) in the journal Urologie A addresses exactly the same issues as have recently received so much attention here in the States.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, mortality, PSA, risk, screening | 1 Comment »
AUA issues full, formal comments on USPSTF draft recommendation
Posted on November 10, 2011 by Sitemaster
On November 8, the American Urological Asociation (AUA) issued its full, formal comment letter on the US Preventive Services Task Force (USPSTF)’s draft recommendation of a “D” grade for the use of PSA screening in healthy men with no symptoms of prostate cancer. The AUA also issued a formal statement for the media.
Filed under: Diagnosis, Risk | Tagged: AUA, Diagnosis, PSA, risk, screening, USPSTF | 3 Comments »
A medical oncologist’s views on the USPSTF draft recommendations
Posted on November 2, 2011 by Sitemaster
An article by a highly regarded specialist in medical oncology in the most recent issue of The ASCO Post discusses recent recommendations from the U.S. Preventive Services Task Force (USPSTF).
Filed under: Diagnosis, Risk | Tagged: Diagnosis, opinion, recommendation, risk, USPSTF | 11 Comments »
Another investigational test may refine data on need for prostate biopsy
Posted on October 23, 2011 by Sitemaster
A newly published paper in the Journal of Urology describes a multi-center, prospective study of the potential of the investigational, urine-based, ProCaM™ assay as a test to offer improved evaluation of the need for prostate biopsy among men with an initial total serum PSA level between 2 and 10 ng/ml.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, epigenetic, ProCaM, PSA, risk, test | 7 Comments »
3 Tesla MRI imaging and the diagnosis of localized prostate cancer
Posted on October 20, 2011 by Sitemaster
It has been noted previously in this blog that we are improving our ability to accurately identify localized prostate cancer using several types of imaging technology.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, identificantion, monitoring, MRI | 28 Comments »
One expert clinician’s very public opinion about the USPSTF recommendation
Posted on October 15, 2011 by Sitemaster
Readers might want to read an article by Ralph de Vere White, MD, the Director of the UC Davis Cancer Center at the University of California Davis in Sacramento, California. Dr. de Vere White is a respected urologic oncologist known to have a strong commitment to shared decision making with patients on issues of cancer risk [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, recommendation, risk, USPSTF | 10 Comments »
The USPSTF recommendation … How to comment
Posted on October 12, 2011 by Sitemaster
The following statement about how to comment on the USPSTF recommendation that uninformed, mass screening of men for risk of prostate cancer is not supported by available evidence can be found on the USPSTF web site:
Filed under: Diagnosis, Risk | Tagged: Diagnosis, risk | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site
